Pfizer Inc. ($PFE) Stock Forecast: Up 2.3% Today

What is Pfizer Inc.?

A leading pharmaceutical company known for its wide range of healthcare products, including vaccines and medications, experienced a strong bullish movement in the market today.

Why is Pfizer Inc. going up?

PFE stock is up 2.3% on Sep 9, 2024 14:35

• The surge in Pfizer's stock was attributed to positive developments in the pharmaceutical industry, particularly related to competitors and collaborations, which increased investor confidence.
• Moderna's recent positive CHMP opinion and approval for an updated COVID-19 vaccine likely contributed to sector-wide optimism and benefitted Pfizer.
• Vaxcyte's vaccine study results, showing strong immune responses and reaching a record high, created a positive sentiment for vaccine-related companies like Pfizer.
• Pfizer's strategic clinical partnership with Acepodia to expedite development in autoimmune diseases indicated potential growth opportunities, driving up the stock price further.

PFE Price Chart

PFE News

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.

https://www.zacks.com/stock/news/2332825/mrna-gets-positive-chmp-opinion-for-updated-covid-19-jab

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

https://www.zacks.com/stock/news/2331600/vaxcyte-stock-hits-record-high-on-pneumococcal-vaccine-study-results

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

https://www.zacks.com/stock/news/2331488/mercks-keytruda-padcev-combo-gets-eu-nod-for-urothelial-carcinoma

Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases - Trane Technologies ( NYSE:TT )

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 ...

https://www.benzinga.com/pressreleases/24/09/n40697053/acepodia-enters-strategic-clinical-collaboration-with-pfizer-to-accelerate-development-of-antibody

What's Going On With Moderna Stock On Tuesday? - Moderna ( NASDAQ:MRNA )

On Tuesday, the Medicines and Healthcare Products Regulatory Agency ( MHRA ) approved Moderna, Inc.'s MRNA updated COVID-19 vaccine, which targets the JN.1 variant of SARS-CoV-2.

https://www.benzinga.com/general/biotech/24/09/40694336/uk-taiwan-approve-modernas-updated-covid-19-shot

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 7.3% Today

Avalanche ($AVAX) Crypto Forecast: Up 6.5% Today

Arbitrum ($ARB) Crypto Forecast: Up 5.9% Today

Aptos ($APT) Crypto Forecast: Up 10.0% Today

Chainlink ($LINK) Crypto Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 14.6% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Worldcoin ($WLD) Crypto Forecast: Up 5.1% Today

Bonk ($BONK) Crypto Forecast: Up 5.5% Today

Pfizer Inc. Price History

09.08.2024 - PFE Stock was up 2.3%

• The surge in Pfizer's stock was attributed to positive developments in the pharmaceutical industry, particularly related to competitors and collaborations, which increased investor confidence.
• Moderna's recent positive CHMP opinion and approval for an updated COVID-19 vaccine likely contributed to sector-wide optimism and benefitted Pfizer.
• Vaxcyte's vaccine study results, showing strong immune responses and reaching a record high, created a positive sentiment for vaccine-related companies like Pfizer.
• Pfizer's strategic clinical partnership with Acepodia to expedite development in autoimmune diseases indicated potential growth opportunities, driving up the stock price further.

26.05.2024 - PFE Stock was down 3.6%

• The bearish movement in Pfizer's stock could be attributed to concerns raised by a recent meeting discussing vaccine recommendations, potentially impacting the company's vaccine sales and future prospects.
• The news of another company's RSV shot being more effective after 18 months, compared to Pfizer's lower effectiveness midway through a second RSV season, might have negatively influenced investor sentiment towards Pfizer's vaccine portfolio.
• Negative outcomes in the healthcare sector, like Pfizer, can sometimes lead to increased scrutiny and skepticism, impacting investor confidence and stock performance.
• The overall market trend of buying blue-chip stocks on the dip might have also contributed to Pfizer's stock decline, as investors may have shifted their focus towards other opportunities in the market, leading to a relative underperformance of Pfizer's stock.

16.09.2023 - PFE Stock was up 6.2%

• Pfizer's stock had a strong bullish movement today.
• The upgrade by Jefferies Financial Group from a "hold" rating to a "buy" rating could have contributed to the bullish movement.
• Pfizer's cut in full-year outlook due to declining sales of Covid-19-related products may have initially caused a retreat in the stock, but it seems that investors have reacted positively to the overall news.
• The bullish movement could also be a result of positive sentiment in the overall market or other factors not mentioned in the provided articles.

22.08.2023 - PFE Stock was down 2.8%

• PFE experienced a strong bearish movement today.
• The comprehensive timeline article mentions myocarditis as a potential side effect of COVID-19 vaccines, including Pfizer's vaccine.
• The article about Pfizer's drug Paxlovid being less effective could have also contributed to the bearish movement.
• The news about insurance coverage delays for COVID-19 vaccines could have added to the negative sentiment surrounding PFE.
• Overall, concerns about vaccine side effects and the effectiveness of Pfizer's drugs, coupled with insurance coverage delays, likely contributed to the bearish movement of PFE today.

13.01.2024 - PFE Stock was down 1.7%

• Today, Pfizer's stock exhibited a noticeable downward trend.
• Recent discussions within US companies regarding layoffs and cost management may have influenced the market's perception of Pfizer's stock.
• The incorporation of Pfizer in conversations about operational efficiency and expense management during earnings calls could have had an adverse effect on the stock's performance.
• The general market sentiment towards biotech stocks likely contributed to the bearish movement experienced by Pfizer's stock.

01.11.2023 - PFE Stock was down 5.1%

• The bearish movement in PFE's stock can be attributed to two main factors:
• 1. Pfizer's decision to end a study of a weight-loss pill due to negative side effects. This news likely raised concerns among investors about the company's pipeline and potential future revenue.
• 2. The positive results from Altimmune's weight loss drug trial, which showed significant weight loss in participants. This news may have diverted investor attention and capital away from Pfizer and towards Altimmune, leading to a decline in PFE's stock.
• In summary, the bearish movement in PFE's stock today can be attributed to concerns over the discontinuation of a weight-loss pill study and the positive results from a competitor's weight loss drug trial.

14.09.2023 - PFE Stock was down 5.9%

• Pfizer has amended its supply agreement with the U.S. government for Paxlovid, a prescription pill for treating Covid-19. This removes uncertainty but may have contributed to the bearish movement as it indicates weaker demand for the drug.
• Pfizer has launched a $3.5 billion cost-cutting program, expecting revenue drops for its Covid-19 vaccine and Paxlovid. This cost-cutting program may have influenced the bearish market movement.
• Pfizer has slashed its revenue forecast by 13% and announced job and expense cuts due to lower-than-expected sales of its COVID-19 products. This downward revision in revenue and cost-cutting measures could have contributed to the bearish sentiment.
• Overall, the bearish movement in PFE today can be attributed to weaker demand for its Covid-19 products, the amended supply agreement for Paxlovid, and the company's cost-cutting initiatives.

06.02.2024 - PFE Stock was up 5.2%

• Pfizer's stock saw a significant bullish surge following endorsements from prominent investors, highlighting its potential for growth and dividends.
• The positive sentiment was further fueled by Pfizer's resilience in the market, trading at a price similar to over a decade ago, making it an attractive opportunity for investors.
• Despite concerns raised by the WHO regarding resistance associated with one of Pfizer's HIV drugs, the overall market optimism and investor confidence in Pfizer's long-term prospects overshadowed these challenges.
• Analysts continue to view Pfizer as a strong buy, emphasizing its undervalued status and potential for substantial upside in the future, contributing to the bullish movement in the stock.

13.11.2023 - PFE Stock was down 7.1%

• The bearish movement in Pfizer's stock today can be attributed to several factors:
• 1. Disappointing sales of COVID-19 products: Pfizer's financial outlook for next year fell short of Wall Street expectations, primarily due to declining sales of COVID-19 treatments and vaccines. The shift from selling these products to governments to the commercial market has resulted in a significant decrease in revenue, causing investor concern.
• 2. Seagen guidance update: Pfizer's stock tumble steepened as Seagen, a company it recently acquired, provided a guidance update that disappointed investors. The expected financial impact from this transaction may have contributed to the bearish movement.
• 3. Lower profit expectations: Pfizer's projected per-share earnings for next year are well below what many had anticipated. This discrepancy between Pfizer's profit expectations and Wall Street projections could have negatively impacted investor sentiment.
• 4. Market competition and acquisitions: The acquisition of Seagen and its potential contribution to Pfizer's revenue by 2030 may have raised concerns about market competition and the company's ability to maintain its growth trajectory.
• Overall, the bearish movement in Pfizer's stock today can be attributed to disappointing sales of COVID-19 products, a guidance update from Seagen, lower profit expectations, and market competition.

11.06.2024 - PFE Stock was up 1.3%

• Pfizer's bullish movement today can be attributed to the positive news regarding the advancement of its once-daily weight-loss pill, danuglipron, which shows promise in the ongoing Phase 1 study. This development indicates potential future revenue streams and market expansion for the company.
• The company's decision to move forward with the once-daily version of the weight-loss pill, despite previous setbacks, demonstrates Pfizer's commitment to innovation and addressing market needs.
• The search for a new Chief Scientific Officer following Dr. Mikael Dolsten's departure may have initially caused some uncertainty in the market, but the overall positive news regarding product development likely overshadowed this aspect, contributing to the bullish movement in the stock.

30.06.2024 - PFE Stock was down 2.0%

• Despite Pfizer delivering robust earnings with revenue exceeding expectations and achieving its first revenue growth since the COVID peak in 2022, the stock encountered a bearish trend.
• The market's response may have been influenced by the substantial decrease in reported net income, showing a 98% year-over-year decline.
• Investors could be expressing worries about Pfizer's dependency on COVID-related products, as the company faces a sharp revenue decline in that particular segment.
• Despite the overall positive market sentiment and Pfizer's increased annual profit forecast driven by strong sales of cancer and heart drugs, the negative impact of the severe net income decline on the stock price was not overcome.

30.06.2024 - PFE Stock was up 1.4%

• Pfizer's recent market movement is linked to its first sales growth since the onset of the pandemic, especially in the field of cancer treatment, demonstrating its capacity to adapt and innovate in evolving market conditions.
• Strong Q2 results, surpassing earnings per share and revenue projections, likely bolstered investor trust in the company's performance and future potential.
• Amid declines in tech stocks and surges in financials and energy stocks, Pfizer's steadfastness and emphasis on areas like cancer treatment resonated with investors, sparking increased interest and a bullish trend for the stock.